Two Sigma Advisers LP Lowers Stock Position in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)

Two Sigma Advisers LP cut its holdings in shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) by 5.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 241,400 shares of the biotechnology company’s stock after selling 14,200 shares during the period. Two Sigma Advisers LP owned 0.60% of Oramed Pharmaceuticals worth $584,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of ORMP. World Equity Group Inc. purchased a new position in shares of Oramed Pharmaceuticals during the fourth quarter worth approximately $48,000. Dimensional Fund Advisors LP grew its position in Oramed Pharmaceuticals by 143.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 118,995 shares of the biotechnology company’s stock valued at $288,000 after buying an additional 70,190 shares during the last quarter. Peapod Lane Capital LLC acquired a new position in Oramed Pharmaceuticals in the 4th quarter valued at $550,000. Boothbay Fund Management LLC increased its stake in Oramed Pharmaceuticals by 2.0% in the 4th quarter. Boothbay Fund Management LLC now owns 845,188 shares of the biotechnology company’s stock valued at $2,045,000 after buying an additional 16,857 shares during the period. Finally, BML Capital Management LLC increased its stake in Oramed Pharmaceuticals by 20.9% in the 4th quarter. BML Capital Management LLC now owns 2,643,907 shares of the biotechnology company’s stock valued at $6,398,000 after buying an additional 457,716 shares during the period. 12.73% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Wall Street Zen cut shares of Oramed Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, May 17th.

Oramed Pharmaceuticals Stock Performance

Shares of ORMP opened at $2.26 on Wednesday. The stock has a market capitalization of $92.32 million, a P/E ratio of 20.55 and a beta of 1.65. Oramed Pharmaceuticals Inc. has a 1 year low of $1.82 and a 1 year high of $3.09. The company’s fifty day moving average is $2.20 and its two-hundred day moving average is $2.29.

Oramed Pharmaceuticals (NASDAQ:ORMP) last issued its earnings results on Thursday, May 15th. The biotechnology company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.16). The business had revenue of $2.00 million for the quarter. Sell-side analysts predict that Oramed Pharmaceuticals Inc. will post -0.03 EPS for the current year.

Oramed Pharmaceuticals Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.